



Taddle Creek

MEDICAL DIRECTIVE

Family Health Team

Title:	<u>Point-of-care Testing</u>	Number:	<u>TCFHT-MD02</u>
Activation Date:	<u>11-June-2013</u>	Review Date:	<u>16-August-2017</u>
Next Review Date:	<u>16-August-2018</u>		

Sponsoring/Contact Person(s)
(name, position, contact particulars): Dr. Christina Biancucci, Lead Physician
790 Bay Street, Suite 522
Toronto, Ontario M5G 1N8
416-591-1222

Shauna Sturgeon, NP
790 Bay Street, Suite 522
Toronto, Ontario M5G 1N8
416-591-1222

Sherry Kennedy, Executive Director – skennedy@tcfht.on.ca
790 Bay Street, Suite 306,
Toronto, Ontario M5G 1N8
416-260-1315 x307

Order and/or Delegated Procedure:

Appendix Attached: No Yes
Title:

Point-of-care (POC) testing:

- Urine analysis by dipstick
- Urine HCG by dipstick or immunoassay (pregnancy test)
- Blood glucose testing using a portable glucometer
- INR testing using a portable INR machine
- Rapid Antigen Detection Test (i.e., Rapid Strep Test) for throat swab

Recipient Patients:

Appendix Attached: No Yes
Title: Appendix A – Authorizer Approval Form

Recipients must:

- Be active patients of a TCFHT physician who has approved this directive by signing the Authorizer Approval Form
- Require POC testing

<p>Authorized Implementers:</p> <p>TCFHT NPs (as indicated on the Implementer Approval Form [Appendix 1]), who upon self-reflection, possess the knowledge, skill and judgement** (College of Nurses of Ontario [CNO], 2011, 2013) to execute and interpret the results of the delegated POC tests. TCFHT NPs must sign the Implementer Approval Form.</p>	<p>Appendix Attached: <input type="checkbox"/> No <input checked="" type="checkbox"/> Yes Title: Appendix B – Implementer Approval Form</p>
<p>Indications:</p> <p>After proper clinical evaluation by the implementer, POC testing is performed to aid in the diagnosis, treatment and/or management of suspected urinary tract infections, proteinuria, glucosuria, ketonuria, hematuria, pregnancy, group A streptococcal pharyngitis, hypoglycemia, hyperglycemia, and for management of anticoagulation therapy.</p> <p>Contraindications: Refusal or lack of verbal consent by the patient or substitute decision maker for the implementer to apply this directive.</p>	<p>Appendix Attached: <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes Title:</p>
<p>Consent:</p> <p>NP will obtain verbal consent from the patient or substitute decision maker prior to implementation of this directive.</p>	<p>Appendix Attached: <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes Title:</p>
<p>Guidelines for Implementing the Order/Procedure:</p> <p>POC testing must be done as outlined by the manufacturers of the testing devices/supplies and all efforts should be made to maintain reliability of the test (i.e., proper storage, proper technique, good dating of supplies, calibration, etc.).</p>	<p>Appendix Attached: <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes Title:</p>
<p>Documentation and Communication:</p> <p>Information regarding the POC testing including the indication for testing, test result, diagnosis, and treatment plan will be documented in the patient’s electronic medical record, in accordance with standard documentation practice. CNO, 2017, 2017)</p>	<p>Appendix Attached: <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes Title:</p>
<p>Review and Quality Monitoring Guidelines:</p> <ul style="list-style-type: none"> • Routine review will occur annually on the anniversary of the activation date. Review will involve a collaboration between the authorizing primary care providers and the authorized implementers. • If new information becomes available between routine reviews, such as the publishing of new clinical practice guidelines, and particularly if this new information has implications for unexpected outcomes, the directive will be reviewed by an authorizing primary care provider and a minimum of one implementer. • At any such time that issues related to the use of this directive are identified, TCFHT must act upon the concerns and immediately undertake a review of the directive by the authorizing 	<p>Appendix Attached: <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes Title:</p>

primary care providers and the authorized implementers.

- This medical directive can be placed on hold if routine review processes are not completed, or if indicated for an ad hoc review. During the hold, implementers cannot perform the procedures under authority of the directive and must obtain direct, patient-specific orders for the procedure until it is renewed.

References:

College of Nurses of Ontario. (2017). *Practice Standard: Documentation, Revised 2008*. Retrieved from https://www.cno.org/globalassets/docs/prac/41001_documentation.pdf

College of Nurses of Ontario. (2017). *Practice Standard: Nurse Practitioner, Revised 2017*. Retrieved from http://www.cno.org/Global/docs/prac/41038_StrdRnec.pdf

College of Nurses of Ontario. (2017). *Practice Standard: Decisions about procedures and authority*. https://www.cno.org/globalassets/docs/prac/41071_decisions.pdf

NOTE:

This medical directive is a revision of “MDO2-Point-of-Care testing,” which was based on TCFHT’s previous medical directive NP-01 entitled, “Point-of-Care Testing for Nurse Practitioners (NPs).” The original directive was revised to reflect the growth of the TCFHT organization. However, the content of MD-02 has been reverted back to reflect an NP-specific medical directive as the breadth of this directive cannot cover other disciplines and their scope of practice or practice regulation. All of the approved NPs and Authorizers for medical directive NP-01 “Point-of-Care Testing for Nurse Practitioners (NPs),” have grandfathered approval for the revised version of TCFHT-MD02 “Point-of-Care Testing.”

